Western Pacific Region Index Medicus

Efficacy and safety of upadacitinib through 140 weeks in Chinese adult and adolescent patients with moderate-to-severe atopic dermatitis: Post hoc analysis of the phase 3 Measure Up 1 and AD Up clinical trials.

Author: Li ZHANG ¹ ; Jinhua XU ² ; Chaoying GU ² ; Min ZHENG ³ ; Meng PAN ⁴ ; Linfeng LI ⁵ ; Michael LANE ⁶ ; Andrew PLATT ⁶ ; Shereen HAMMAD ⁶ ; Qichen FAN ⁶ ; Xinghua GAO ¹
Author Information

1. Department of Dermatology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, China.
2. Department of Dermatology, Huashan Hospital, Fudan University, Shanghai 200040, China.
3. Department of Dermatology, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, China.
4. Department of Dermatology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
5. Department of Dermatology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
6. AbbVie Inc., North Chicago, IL 60064, USA.
Publication Type:Journal Article
From: Chinese Medical Journal 2025;138(13):1633-1634
CountryChina
Language:English